These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16793238)

  • 41. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
    Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients.
    Hori H; Yoshimura R; Katsuki A; Hayashi K; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    Int J Psychiatry Clin Pract; 2012 Jun; 16(2):138-42. PubMed ID: 22136174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prefrontal cognitive deficits in patients with schizophrenia treated with atypical or conventional antipsychotics.
    Müller U; Werheid K; Hammerstein E; Jungmann S; Becker T
    Eur Psychiatry; 2005 Jan; 20(1):70-3. PubMed ID: 15642448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Differentiation of deficit and non-deficit schizophrenia based on cognitive functions].
    Polgár P
    Ideggyogy Sz; 2011 Mar; 64(3-4):128-32. PubMed ID: 21545010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Longitudinal Wisconsin card sorting performance in schizophrenia patients in rehabilitation.
    Bryson G; Greig T; Lysaker P; Bell M
    Appl Neuropsychol; 2002; 9(4):203-9. PubMed ID: 12584074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls.
    Ahn YM; Lee KY; Kim CE; Kim JJ; Kang DY; Jun TY; Choi JS; Chung IW; Kim SH; Hwang SS; Kim YS
    J Clin Psychopharmacol; 2009 Apr; 29(2):117-23. PubMed ID: 19512972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.
    Wittorf A; Sickinger S; Wiedemann G; Klingberg S
    Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program.
    Menzin J; Boulanger L; Friedman M; Mackell J; Lloyd JR
    Psychiatr Serv; 2003 May; 54(5):719-23. PubMed ID: 12719504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Executive and amnestic functions of a group of first-degree relatives of schizophrenic patients].
    Laurent A; d'Amato T; Naegele B; Murry P; Baro P; Foussard N; Spitz F; Dalery J
    Encephale; 2000; 26(5):67-74. PubMed ID: 11192806
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort.
    Husa AP; Moilanen J; Murray GK; Marttila R; Haapea M; Rannikko I; Barnett JH; Jones PB; Isohanni M; Remes AM; Koponen H; Miettunen J; Jääskeläinen E
    Psychiatry Res; 2017 Jan; 247():130-138. PubMed ID: 27888683
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sex differences in the association between serum BDNF and cognitive impairment in schizophrenia patients using various antipsychotics.
    Dong R; Zhao NO; Wu HE; Yu L; Zhang XY
    J Psychiatr Res; 2021 Jun; 138():492-499. PubMed ID: 33971483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study.
    Husa AP; Rannikko I; Moilanen J; Haapea M; Murray GK; Barnett J; Jones PB; Isohanni M; Koponen H; Miettunen J; Jääskeläinen E
    Schizophr Res; 2014 Sep; 158(1-3):134-41. PubMed ID: 25034761
    [TBL] [Abstract][Full Text] [Related]  

  • 55. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.
    Woodward ND; Jayathilake K; Meltzer HY
    Schizophr Res; 2007 Feb; 90(1-3):86-96. PubMed ID: 17123785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is there a decline in cognitive functions after combined electroconvulsive therapy and antipsychotic therapy in treatment-refractory schizophrenia?
    Pawełczyk A; Kołodziej-Kowalska E; Pawełczyk T; Rabe-Jabłońska J
    J Nerv Ment Dis; 2015 Mar; 203(3):182-6. PubMed ID: 25668655
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia.
    Weickert TW; Goldberg TE
    Curr Psychiatry Rep; 2005 Aug; 7(4):304-10. PubMed ID: 16098285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia.
    Kudo N; Yamamori H; Ishima T; Nemoto K; Yasuda Y; Fujimoto M; Azechi H; Niitsu T; Numata S; Ikeda M; Iyo M; Ohmori T; Fukunaga M; Watanabe Y; Hashimoto K; Hashimoto R
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):150-156. PubMed ID: 32022478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.